Global Postmenopausal Osteoporosis Treatment Market is valued approximately at USD 9.12 billion in 2022 and is anticipated to grow with a growth rate of more than 5.2% over the forecast period 2023-2030. Postmenopausal osteoporosis is a condition that occurs in women after menopause, typically in their 50s or 60s. It is a type of osteoporosis that is caused by the decrease in estrogen levels that occurs during menopause. Estrogen is an important hormone for maintaining bone density and when levels drop, bones can become weaker and more brittle, leading to an increased risk of fractures. The Postmenopausal Osteoporosis Treatment market is expanding because of factors such as increasing Prevalence of Osteoporosis and growing geriatric population.
One of the risk factors for poor bone density and the subsequent development of osteoporosis in women after menopause is ageing. Other risk factors include smoking, drinking alcohol, using gonadotropins, thyroid hormone in excess and using other medications used to treat various conditions. According to data from the International Menopause Society (IMS), Osteoporosis has affect more than 200 million women on a global level in 2021, and one in three women over 50 is predicted to have an osteoporosis fracture. The postmenopausal osteoporosis market has grown significantly as a result of the ageing population and lifestyle changes. The older population is more susceptible to osteoporosis, their population growth is anticipated to be a major driving force behind the market’s expansion. In the World Health Organization’s October 2021 report, for instance, it is predicted that the number of adults 60 and older will rise from 1 billion in 2020 to 1.4 billion by 2030 and 2.1 billion by 2050. The need for treatment of postmenopausal osteoporosis in the elderly population is thus expected to rise during the forecast period, leading to market growth. In addition, rising research and development activities and rapid technological development and continuing clinical trials is creating lucrative growth to the market. However, high Cost of Postmenopausal osteoporosis treatment and low awareness about postmenopausal osteoporosis stifles market growth throughout the forecast period of 2023-2030.
The key regions considered for the Global Postmenopausal Osteoporosis Treatment Market study includes Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America dominated the market in 2022 with largest market share owing to the dominance of branded treatment and the region’s increasing disease prevalence. Asia Pacific is expected to grow significantly during the forecast period, owing to factors such as rising geriatric and target populations, an increase in the number of collaborations for treatment development, geographic expansion of key players, and active participation of government and nonprofit organizations in the market space.
Major market player included in this report are:
Teva Pharmaceuticals Industries Ltd.
Merck & Co.
Eli Lilly and Company
AbbVie (Allergan plc.)
F. Hoffmann-La Roche Ltd.
Sun Pharmaceutical Industries Ltd
Recent Developments in the Market:
Ø In June 2022, Chugai Pharma China Co., Ltd., a branch of Chugai Pharmaceutical Co., Ltd., launched Edirol (eldecalcitol) in China after receiving permission from the China National Medical Products Administration (NMPA) for the treatment of postmenopausal osteoporosis. Chugai created Edirol, a derivative of active vitamin D3.
Ø In January 2021, The Asia Pacific Consortium on Osteoporosis (APCO) has proposed pan-Asia Pacific clinical practise standards that will primarily target a wide range of high-risk individuals in order to screen, diagnose, and manage osteoporosis. The plan is anticipated to further increase regional awareness, which will aid in the expansion of the Asia-Pacific market.
Global Postmenopausal Osteoporosis Treatment Market Report Scope:
ü Historical Data – 2020 – 2021
ü Base Year for Estimation – 2022
ü Forecast period – 2023-2030
ü Report Coverage – Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
ü Segments Covered – Drug Type, Distribution Channel, Region
ü Regional Scope – North America; Europe; Asia Pacific; Latin America; Middle East & Africa
ü Customization Scope – Free report customization (equivalent up to 8 analyst’s working hours) with purchase. Addition or alteration to country, regional & segment scope*
The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.
The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and Drug Typeofferings of key players. The detailed segments and sub-segment of the market are explained below:
By Drug Type:
Hormone Replacement Therapy
Parathyroid Hormone Therapy
By Distribution Channel:
Middle East & Africa
Rest of Middle East & Africa